Palbociclib combined with endocrine treatment in hormone receptor-positive, HER2-negative breast cancer patients with high relapse risk after neoadjuvant chemotherapy: subgroup analyses of premenopausal patients in PENELOPE-B

Frederik Marmé; Miguel Martín; Michael Untch; Christian Thode; H. Bonnefoi; S.-B. Kim; Harry D. Bear; Nicole Mc Carthy; Karen A. Gelmon; José Á. García-Sáenz; Catherine M. Kelly; Toralf Reimer; Olga Valota; Masakazu Toi; H.S. Rugo; Michael Gnant; Andreas Makris; Martina Bassy; Zhe Zhang; Jenny Furlanetto; Valentina Nekljudova; S. Loibl

doi:10.1016/j.esmoop.2024.103466

Abstract

The PENELOPE-B study demonstrated that the addition of 1-year post-neoadjuvant palbociclib to endocrine therapy (ET) in patients with high-risk early breast cancer (BC) did not improve invasive disease-free survival (iDFS) compared to placebo. Here, we report results for premenopausal women.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Marmé et al. (2024) studied this question.

synapsesocial.com/papers/68e66b13b6db6435875f61e8 https://doi.org/10.1016/j.esmoop.2024.103466

View Full Paper

Ask AI

Bookmark

Share

Palbociclib combined with endocrine treatment in hormone receptor-positive, HER2-negative breast cancer patients with high relapse risk after neoadjuvant chemotherapy: subgroup analyses of premenopausal patients in PENELOPE-B

Abstract

Discussion

Cite This Study

Palbociclib combined with endocrine treatment in hormone receptor-positive, HER2-negative breast cancer patients with high relapse risk after neoadjuvant chemotherapy: subgroup analyses of premenopausal patients in PENELOPE-B

Abstract

Discussion

Cite This Study

Keep reading

Keep reading